First, in patients, we observed that aggressive AML forms carrying the FLT3‐ITD mutation display significantly higher endoglin expression on the surface of stromal cells, compared to FLT3 wild‐type AML (Fig 6A; Dataset EV4). The gene discussed is FLT3; the disease is acute myeloid leukemia.